This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Kole T. Roybal, Alex Marson and Yvonne Y. Chen
Date: January 25 - 27, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Sponsored by AstraZeneca, BioLegend, Inc., BlueRock Therapeutics, Nektar Therapeutics, Novo Nordisk A/S and TCR² Therapeutics
For important information on the coronavirus, please click here
Summary of Meeting:
Cellular therapeutics are poised to be a next pillar of medicine along with small molecules and biologics. These living drugs have a unique capacity for more complex decision-making and therapeutic responses, potentially alleviating the need for chronic treatment. Next-generation cell therapies will need to adapt and respond to disease progression, essentially functioning as microscopic “physicians” capable of sensing, diagnosing, and eradicating disease via multifaceted mechanisms that are difficult to resist yet similar to our natural immune system. Advances in engineered T cell therapeutics are being FDA approved and are now transforming treatment plans for cancers that previously had few therapeutic options. While there have been unprecedented complete responses in a subset of hematological malignancies, the current therapies can show significant toxicity and on the other hand show a lack of efficacy in solid tumors. Beyond cancer, engineered cell therapies could have significant impact in the treatment of autoimmunity, metabolic disorders and in regenerative medicine. This conference will therefore cover next-generation cellular engineering approaches designed to tackle refractory diseases such as solid tumors, while also addressing the higher safety requirements for diseases beyond late-stage metastatic cancers. This conference brings together clinically minded cell therapists, synthetic biologists, genome and protein engineers, systems biologists, and immunologists; this combined expertise is essential to establish cells as a safe and effective therapeutic strategy across a range of diseases. Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.
Scholarship Deadline: November 1 2020
Abstract Deadline: December 15 2020
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AstraZenecaBioLegend, Inc.BlueRock TherapeuticsNektar TherapeuticsNovo Nordisk A/STCR² TherapeuticsThermo Fisher Scientific Inc.
We gratefully acknowledge additional support for this conference from:
AdipoGen Life SciencesAmerican Association for Cancer Research (AACR)DCVC BioNanoString Technologies, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA254054-01
Funding for this conference was made possible (in part) by 1R13CA254054-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found